FY2025 Earnings Forecast for ABVX Issued By Lifesci Capital

ABIVAX Société Anonyme (NASDAQ:ABVX) – Investment analysts at Lifesci Capital issued their FY2025 EPS estimates for ABIVAX Société Anonyme in a research report issued to clients and investors on Tuesday, March 25th. Lifesci Capital analyst S. Slutsky anticipates that the company will post earnings per share of ($3.14) for the year. The consensus estimate for ABIVAX Société Anonyme’s current full-year earnings is ($2.83) per share.

A number of other research firms also recently issued reports on ABVX. Morgan Stanley reaffirmed an “equal weight” rating and set a $12.00 price objective on shares of ABIVAX Société Anonyme in a report on Thursday, March 20th. Citizens Jmp raised ABIVAX Société Anonyme to a “strong-buy” rating in a research note on Wednesday, December 4th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $33.00 price objective on shares of ABIVAX Société Anonyme in a report on Friday, January 10th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $38.00.

ABIVAX Société Anonyme Price Performance

ABVX stock opened at $7.34 on Wednesday. The firm has a 50 day simple moving average of $6.77 and a two-hundred day simple moving average of $8.43. ABIVAX Société Anonyme has a one year low of $5.50 and a one year high of $16.63.

Institutional Investors Weigh In On ABIVAX Société Anonyme

Institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC bought a new stake in ABIVAX Société Anonyme in the fourth quarter valued at approximately $29,000. R Squared Ltd purchased a new position in shares of ABIVAX Société Anonyme in the fourth quarter worth $36,000. Bank of America Corp DE raised its holdings in ABIVAX Société Anonyme by 56.1% during the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after buying an additional 1,990 shares during the last quarter. Ameriprise Financial Inc. purchased a new stake in ABIVAX Société Anonyme during the 4th quarter valued at $85,000. Finally, Guggenheim Capital LLC bought a new stake in ABIVAX Société Anonyme in the 4th quarter worth $92,000. 47.91% of the stock is currently owned by hedge funds and other institutional investors.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.